481 related articles for article (PubMed ID: 21812892)
21. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
Schramm TK; Gislason GH; Vaag A; Rasmussen JN; Folke F; Hansen ML; Fosbøl EL; Køber L; Norgaard ML; Madsen M; Hansen PR; Torp-Pedersen C
Eur Heart J; 2011 Aug; 32(15):1900-8. PubMed ID: 21471135
[TBL] [Abstract][Full Text] [Related]
22. Database evaluation of the effects of long-term rosiglitazone treatment on cardiovascular outcomes in patients with type 2 diabetes.
Loebstein R; Dushinat M; Vesterman-Landes J; Silverman B; Friedman N; Katzir I; Kurnik D; Lomnicky Y; Kokia E; Halkin H
J Clin Pharmacol; 2011 Feb; 51(2):173-80. PubMed ID: 20484611
[TBL] [Abstract][Full Text] [Related]
23. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007.
Walker AM; Koro CE; Landon J
Pharmacoepidemiol Drug Saf; 2008 Aug; 17(8):760-8. PubMed ID: 18383443
[TBL] [Abstract][Full Text] [Related]
24. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis.
Pantalone KM; Kattan MW; Yu C; Wells BJ; Arrigain S; Jain A; Atreja A; Zimmerman RS
Acta Diabetol; 2009 Jun; 46(2):145-54. PubMed ID: 19194648
[TBL] [Abstract][Full Text] [Related]
25. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
[TBL] [Abstract][Full Text] [Related]
26. Impact of glycaemic control, hypertension and insulin treatment on general and cause-specific mortality: an Italian population-based cohort of type II (non-insulin-dependent) diabetes mellitus.
Bruno G; Merletti F; Boffetta P; Cavallo-Perin P; Bargero G; Gallone G; Pagano G
Diabetologia; 1999 Mar; 42(3):297-301. PubMed ID: 10096781
[TBL] [Abstract][Full Text] [Related]
27. All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides.
Mannucci E; Monami M; Masotti G; Marchionni N
Diabetes Metab Res Rev; 2004; 20(1):44-7. PubMed ID: 14737744
[TBL] [Abstract][Full Text] [Related]
28. Metformin use and survival after colorectal cancer: A population-based cohort study.
Mc Menamin ÚC; Murray LJ; Hughes CM; Cardwell CR
Int J Cancer; 2016 Jan; 138(2):369-79. PubMed ID: 26331456
[TBL] [Abstract][Full Text] [Related]
29. Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality.
Monami M; Balzi D; Lamanna C; Barchielli A; Masotti G; Buiatti E; Marchionni N; Mannucci E
Diabetes Metab Res Rev; 2007 Sep; 23(6):479-84. PubMed ID: 17385195
[TBL] [Abstract][Full Text] [Related]
30. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
31. Incidence of dementia is increased in type 2 diabetes and reduced by the use of sulfonylureas and metformin.
Hsu CC; Wahlqvist ML; Lee MS; Tsai HN
J Alzheimers Dis; 2011; 24(3):485-93. PubMed ID: 21297276
[TBL] [Abstract][Full Text] [Related]
32. The impact of glucose lowering treatment on long-term prognosis in patients with type 2 diabetes and myocardial infarction: a report from the DIGAMI 2 trial.
Mellbin LG; Malmberg K; Norhammar A; Wedel H; Rydén L;
Eur Heart J; 2008 Jan; 29(2):166-76. PubMed ID: 18156614
[TBL] [Abstract][Full Text] [Related]
33. Insulin use is not significantly predictive for prostate cancer mortality in diabetic patients: a 12-year follow-up study.
Tseng CH
BJU Int; 2012 Sep; 110(5):668-73. PubMed ID: 22300458
[TBL] [Abstract][Full Text] [Related]
34. Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with Type 2 diabetes in a Taiwanese population cohort.
Wahlqvist ML; Lee MS; Hsu CC; Chuang SY; Lee JT; Tsai HN
Parkinsonism Relat Disord; 2012 Jul; 18(6):753-8. PubMed ID: 22498320
[TBL] [Abstract][Full Text] [Related]
35. Impact of oral antihyperglycemic therapy on all-cause mortality among patients with diabetes in the Veterans Health Administration.
Kahler KH; Rajan M; Rhoads GG; Safford MM; Demissie K; Lu SE; Pogach LM
Diabetes Care; 2007 Jul; 30(7):1689-93. PubMed ID: 17440170
[TBL] [Abstract][Full Text] [Related]
36. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea.
Becker ML; Aarnoudse AJ; Newton-Cheh C; Hofman A; Witteman JC; Uitterlinden AG; Visser LE; Stricker BH
Pharmacogenet Genomics; 2008 Jul; 18(7):591-7. PubMed ID: 18551039
[TBL] [Abstract][Full Text] [Related]
37. Metformin may reduce bladder cancer risk in Taiwanese patients with type 2 diabetes.
Tseng CH
Acta Diabetol; 2014 Apr; 51(2):295-303. PubMed ID: 24509842
[TBL] [Abstract][Full Text] [Related]
38. Extended follow-up and spatial analysis of the American Cancer Society study linking particulate air pollution and mortality.
Krewski D; Jerrett M; Burnett RT; Ma R; Hughes E; Shi Y; Turner MC; Pope CA; Thurston G; Calle EE; Thun MJ; Beckerman B; DeLuca P; Finkelstein N; Ito K; Moore DK; Newbold KB; Ramsay T; Ross Z; Shin H; Tempalski B
Res Rep Health Eff Inst; 2009 May; (140):5-114; discussion 115-36. PubMed ID: 19627030
[TBL] [Abstract][Full Text] [Related]
39. The joint effects of different types of glucose-lowering treatment and duration of diabetes on total and cardiovascular mortality among subjects with type 2 diabetes.
Khalangot M; Tronko M; Kravchenko V; Kulchinska J; Hu G
Diabetes Res Clin Pract; 2008 Oct; 82(1):139-47. PubMed ID: 18703252
[TBL] [Abstract][Full Text] [Related]
40. Association between congestive heart failure and hospitalization in patients with type 2 diabetes mellitus receiving treatment with insulin or pioglitazone: a retrospective data analysis.
Rajagopalan R; Rosenson RS; Fernandes AW; Khan M; Murray FT
Clin Ther; 2004 Sep; 26(9):1400-10. PubMed ID: 15531002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
